+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists



The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists



Pharmacogenomics Journal 2(3): 182-190



Genetic variants are risk factors for coronary disease, but their role in recurrent events and in response to treatment is less clear. We genotyped genetic variants implicated in primary coronary disease in 924 Caucasians with acute coronary syndromes participating in the OPUS-TIMI16 trial of the GPIIb/IIIa antagonist orbofiban. These were the platelet glycoprotein (GP) receptors GPIIIa, GPIa, GPIbalpha; platelet ligands beta-fibrinogen and von Willebrand Factor (vWF); interleukins (IL) IL-1RN, and IL-6; adhesion proteins E-selectin and P-selectin; and metalloproteinase MMP-9. Cox modelling of all genetic variants demonstrated no significant impact on the composite endpoint (P = 0.88), which included myocardial infarction (MI), death, recurrent ischemia, urgent revascularisation and stroke, but a significant impact on recurrent myocardial infarction alone (chi(2) = 20.4, 10 df, P = 0.04). There was a significant interaction of the polymorphisms with orbofiban treatment influencing bleeding outcomes (P = 0.004). Thus, genetic polymorphisms may be associated with subsequent myocardial infarction, and may also be associated with treatment-associated bleeding among coronary patients.

Accession: 011485324

Download citation: RISBibTeXText

PMID: 12082590

DOI: 10.1038/sj.tpj.6500100


Related references

Risk of bleeding with glycoprotein IIb/IIIa receptor antagonists in patients undergoing coronary intervention at a community hospital. Pharmacotherapy 20(3): 340, March, 2000

Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin K antagonists. Journal des Maladies Vasculaires 39(4): 248-255, 2016

Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention. Journal of Thrombosis and Thrombolysis 11(3): 203-209, 2001

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 354(9195): 2019-2024, 2000

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. Lancet (North American Edition) 354(9195): 2019-2024, Dec 11, 1999

Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris. American Journal of Cardiology 102(2): 160-164, 2008

Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 98(12): 3256-3260, 2001

Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Canadian Journal of Cardiology 23(12): 963-970, 2007

Improved outcomes with low-molecular-weight heparin versus unfractionated heparin for patients receiving glycoprotein IIb/IIIa antagonists for acute coronary syndromes Results from the CRUSADE initiative. Circulation 108(17 Supplement): IV-579-IV-580, October 28, 2003

GP-IIb/IIIa antagonists expand the anti thrombotic therapy of acute coronary syndromes. Satellite symposium during the 21st Congress of the European Society of Cardiology. Barcelona, August 1999. Deutsche Medizinische Wochenschrift 124(48 Suppl): 1-4, 2000

Aspirin resistance is associated with platelet GP IIb/IIIa receptor polymorphism PLA2 and thrombotic events in coronary heart disease patients undergoing percutaneous coronary procedures. European Heart Journal 21(Abstract Supplement): 648, August-September, 2000

A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. Cardiovascular Therapeutics 34(5): 330-336, 2016

Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients. Journal of Clinical Pharmacology 44(11): 1328-1332, 2004

GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Journal of Thrombosis and Haemostasis 3(2): 312-320, 2005